STOCK TITAN

Point72 Group and S.A. Cohen File Schedule 13G for APVO — 9.1% Ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Point72 entities and Steven A. Cohen disclosed beneficial ownership of 299,944 shares of Aptevo Therapeutics Inc. common stock, representing 9.1% of the class as of the close of business on September 16, 2025. The filing states Point72 Asset Management and Point72 Capital Advisors have shared voting and dispositive power over these shares through their management of Point72 Associates, while Mr. Cohen controls those entities. The statement includes a certification that the shares were not acquired to change or influence control of the issuer. The reporting parties executed a joint filing agreement (Exhibit 99.1) and provided principal business address information.

Positive

  • Material stake disclosed: Reporting persons hold 299,944 shares, equal to 9.1% of Aptevo's common stock.
  • Clear ownership chain: Filing explains that shares are held by Point72 Associates with investment and voting power held by Point72 Asset Management and control via Point72 Capital Advisors and Steven A. Cohen.
  • Compliance and certification: Includes joint filing agreement (Exhibit 99.1) and a certification that the shares were not acquired to change or influence control.

Negative

  • None.

Insights

TL;DR: Point72 group reports a 9.1% stake in APVO with shared voting/dispositive power; filing declares no intent to change control.

The Schedule 13G reports an aggregate position of 299,944 shares (9.1% of the class) held via Point72 Associates and managed by Point72 Asset Management, with Point72 Capital Advisors as general partner and Steven A. Cohen controlling those entities. The filing is consistent with passive investor disclosure under Rule 13d-1 and includes the required joint filing agreement. For investors, the disclosure confirms a material minority stake and identifies the parties with voting and disposition authority while stating the position is not intended to alter issuer control.

TL;DR: A well-structured 13G shows shared power among Point72 entities and a certification of passive intent.

The submission clarifies the ownership chain: Point72 Associates holds the shares, Point72 Asset Management maintains investment and voting power under an investment management agreement, Point72 Capital Advisors is the general partner, and Steven A. Cohen controls the entities. The filing includes the signature block and joint filing agreement reference, meeting formal disclosure requirements. The explicit certification that the securities were not acquired to influence control is an important compliance statement under the Exchange Act.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:09/17/2025
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:09/17/2025
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:09/17/2025
Exhibit Information

Exhibit 99.1: Joint Filing Agreement

FAQ

How many Aptevo (APVO) shares does Point72 report owning?

The filing reports 299,944 shares, representing 9.1% of the class as of the close of business on September 16, 2025.

Which Point72 entities are named in the Schedule 13G for APVO?

The filing is by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen (joint filing).

Does the filing state the Point72 group intends to change control of Aptevo?

No. The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

What voting and dispositive powers are reported for the Point72 filers?

The cover page shows 0 sole voting and dispositive power and 299,944 shared voting and dispositive power for each reporting person.

Where is the principal business address for the reporting persons?

The principal business office is listed as 72 Cummings Point Road, Stamford, CT 06902.
Aptevo Therapeutics Inc

NASDAQ:APVO

View APVO Stock Overview

APVO Rankings

APVO Latest News

APVO Latest SEC Filings

APVO Stock Data

4.42M
997.08k
Biotechnology
Pharmaceutical Preparations
Link
United States
SEATTLE